A detailed history of Black Rock Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,916,127 shares of IMVT stock, worth $135 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,916,127
Previous 4,476,800 9.81%
Holding current value
$135 Million
Previous $145 Million 10.27%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.1 - $31.61 $11 Million - $13.9 Million
439,327 Added 9.81%
4,916,127 $130 Million
Q1 2024

May 10, 2024

SELL
$30.27 - $43.79 $1.63 Million - $2.36 Million
-53,916 Reduced 1.19%
4,476,800 $145 Million
Q4 2023

Feb 13, 2024

BUY
$31.31 - $44.19 $12.5 Million - $17.6 Million
399,051 Added 9.66%
4,530,716 $191 Million
Q3 2023

Nov 13, 2023

SELL
$18.55 - $39.96 $1.29 Million - $2.78 Million
-69,649 Reduced 1.66%
4,131,665 $159 Million
Q2 2023

Aug 11, 2023

BUY
$14.2 - $23.75 $3.75 Million - $6.27 Million
264,133 Added 6.71%
4,201,314 $79.7 Million
Q1 2023

May 12, 2023

BUY
$15.27 - $19.72 $118,449 - $152,968
7,757 Added 0.2%
3,937,181 $61.1 Million
Q4 2022

Feb 13, 2023

BUY
$6.59 - $17.75 $2.79 Million - $7.5 Million
422,750 Added 12.06%
3,929,424 $69.7 Million
Q3 2022

Nov 14, 2022

SELL
$3.93 - $6.37 $489,819 - $793,931
-124,636 Reduced 3.43%
3,506,674 $19.6 Million
Q2 2022

Aug 12, 2022

BUY
$3.38 - $5.65 $937,760 - $1.57 Million
277,444 Added 8.27%
3,631,310 $14.2 Million
Q1 2022

May 12, 2022

BUY
$5.06 - $8.77 $146,056 - $253,146
28,865 Added 0.87%
3,353,866 $18.5 Million
Q4 2021

Feb 10, 2022

BUY
$7.33 - $9.32 $557,080 - $708,320
76,000 Added 2.34%
3,325,001 $28.3 Million
Q3 2021

Nov 09, 2021

BUY
$7.01 - $11.37 $1.02 Million - $1.66 Million
146,214 Added 4.71%
3,249,001 $28.2 Million
Q2 2021

Aug 11, 2021

BUY
$9.4 - $16.85 $29.2 Million - $52.3 Million
3,102,787 New
3,102,787 $32.8 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.